Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces mean body weight reductions of 20.9% at 72 weeks by delaying gastric emptying, suppressing ghrelin rebound, and enhancing glucose-dependent insulin secretion
Depending on your metabolism and activity levels, benefits can last from a few days to several weeks on average
It is good for women put on birth control pills who want to get off them
Apr 1 2012;4(2):167-175
Cai, Brian Toy, Benjamin Martin, Ruochong Fan, Erik Westlund, Diep Tran, Akihiko Nishimura, Haeun Lee, Theodore Leng, Paul Nagy, Nestoras Mathioudakis, Linying Zhang, Michelle Hribar, Aiyin Chen, Karen Armbrust, Kerry Goetz, Sally Baxter, Michael V
The SELECT trial addressed this gap by enrolling individuals with overweight or obesity and established cardiovascular disease but without diabetes, demonstrating a 20% reduction in MACE with semaglutide